COVID-19 vaccine roll-out started in the UK on 8 December 2020. Results from Phase 3 clinical trials have been published for all the vaccines approved for use in the UK. But how does the performance of vaccines under real world conditions differ from clinical trial results? When will we able to observe the impacts of the COVID-19 vaccination programme?
The Government’s COVID-19 Winter Plan, relies on three things to provide the UK with a “route back to normality”: vaccines, treatments and testing. In addition to laboratory-based tests, lateral flow tests are being used for rapid testing in communities and workplaces. What are the latest data on how good these tests are? What are the pros and cons of using them for mass testing?
In recent months several new variants of the SARS-CoV-2 virus have been detected in various countries around the world. This article examines how these variants arise, how genetic variation might affect the characteristics of the virus, and the possible impact that these new variants might have on the course of the pandemic.
The rapid production of safe, effective and consistent vaccines is essential for supporting COVID-19 immunisation programmes in the UK and globally. However, manufacturing vaccines is challenging for various reasons that include the complex processes involved, the specialist knowledge and experience required, and the natural variability of the biological materials and systems used. Urgent demand is leading to manufacturers and governments taking on significant financial risks in order to speed up production. What is the UK Government doing to accelerate vaccine manufacture? How are vaccines made? Why is manufacturing vaccines at large scales so challenging?
The digital divide is the gap between people in society who have full access to digital technologies (such as the internet and computers) and those who do not. Concerns about the digital divide have been particularly acute during the COVID-19 pandemic as the internet and digital devices have played an important role in allowing people to access services, attend medical appointments and stay in touch with friends and family. What impact has the digital divide had on children and adults in the UK during the COVID-19 pandemic and what has been done to tackle it?
As mass immunisation against COVID-19 begins in the UK and elsewhere, the safety of the recently approved Pfizer/BioNTech vaccine is being closely monitored. How is vaccine safety measured and what happens when side effects are found?
Since early 2020, the UK has been carrying out wastewater monitoring for COVID-19. Wastewater samples are collected regularly across the country and analysed for SARS-CoV-2, the virus that causes COVID-19. Wastewater monitoring is part of monitoring systems to detect new COVID-19 outbreaks and support test and trace approaches. How can SARS-CoV-2 be detected in wastewater? How can wastewater monitoring be used as part of the response to the COVID-19 outbreak? And how are wastewater monitoring programmes being used across the UK and worldwide?
With several potential vaccines approaching the end of clinical trials, a new focus is how they will be approved for general use. How does this process work? Who will receive the first COVID-19 vaccines when they become available in the UK? What are public attitudes towards a COVID-19 vaccine in the UK?
Media headlines have predicted an increase in mental ill health among NHS staff during the COVID-19 pandemic. This POSTnote gives an overview of the scale and quality of current evidence on the mental health and well-being of NHS staff before and during the pandemic. It also discusses how staff are supported and the options for introducing other effective interventions as the pandemic continues.
The COVID-19 Winter Plan, published 23 November, relies on three factors to provide the UK with a “route back to normality”: vaccines, treatments and testing. In addition to PCR testing, lateral flow devices are now being rolled out across England and Wales for the rapid testing of certain occupational groups, community testing and as an alternative to self-isolation following exposure to the virus. How well validated have these tests been? Are they accurate enough for their proposed purposes? And how have they performed to date in mass testing trials?
The use of technology to perpetrate domestic abuse, referred to as tech abuse, has become increasingly common. Domestic abuse charity Refuge reported that in 2019, 72% of women accessing its services said that they had been subjected to technology-facilitated abuse. Common devices such as smartphones and tablets can be misused to stalk, harass, impersonate and threaten victims. Some groups have raised concerns that the growing use of internet-connected home devices (such as smart speakers) may provide perpetrators with a wider and more sophisticated range of tools to harm victims. How is technology being used to perpetrate domestic abuse, how can this be prevented and what role can technology play in supporting victims?
Vaccines are the most powerful tool against infectious diseases, and there are over 200 COVID-19 vaccines in development. Which COVID-19 vaccines are closer to the finish line? Which ones have been approved already for use in humans? When will a vaccine be available in the UK?
People’s behaviour has a major role in the success of test, trace and isolate programmes. Uncertainty about whether to report symptoms, low perceived risk of COVID-19 disease and concerns about the consequences of self-isolation are among the barriers to adherence. Has the Scientific Advisory Group for Emergencies looked at adherence to TTI? What evidence is there on people’s understanding and willingness to be tested, provide contact details and self-isolate? Is there anything that can be done to improve this?
Test, trace and isolate programmes across the UK are under pressure as COVID-19 cases rise in all age groups and demand for tests grows. Further pressure comes from people seeking tests because they have symptoms caused by other respiratory viruses but need a test in order to rule out COVID-19. The Scientific Advisory Group on Emergencies has described the impact of current test and tracing on the transmission of the virus as “marginal”. How does test and trace work and what are the current challenges limiting its effectiveness in reducing COVID-19 cases?
Some occupational groups have experienced higher rates of both COVID-19 infections and related deaths. Many people who work within these groups are involved in caring for people or patients that are more likely to be infected, or have otherwise been unable to work from home during the peaks of transmission. Which occupations have been most affected, what factors are contributing to this risk and are some sectors of the population being impacted more than others?